Tenaya Therapeutics (TNYA) Competitors $0.60 -0.03 (-4.94%) As of 06/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNYA vs. TERN, TNGX, AQST, GLUE, ALLO, TVRD, PVLA, CADL, TNXP, and CYRXShould you be buying Tenaya Therapeutics stock or one of its competitors? The main competitors of Tenaya Therapeutics include Terns Pharmaceuticals (TERN), Tango Therapeutics (TNGX), Aquestive Therapeutics (AQST), Monte Rosa Therapeutics (GLUE), Allogene Therapeutics (ALLO), Cara Therapeutics (TVRD), Palvella Therapeutics (PVLA), Candel Therapeutics (CADL), Tonix Pharmaceuticals (TNXP), and Cryoport (CYRX). These companies are all part of the "pharmaceutical products" industry. Tenaya Therapeutics vs. Its Competitors Terns Pharmaceuticals Tango Therapeutics Aquestive Therapeutics Monte Rosa Therapeutics Allogene Therapeutics Cara Therapeutics Palvella Therapeutics Candel Therapeutics Tonix Pharmaceuticals Cryoport Tenaya Therapeutics (NASDAQ:TNYA) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, community ranking, risk and valuation. Is TNYA or TERN more profitable? Terns Pharmaceuticals' return on equity of -32.76% beat Tenaya Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tenaya TherapeuticsN/A -86.17% -71.14% Terns Pharmaceuticals N/A -32.76%-31.33% Do analysts prefer TNYA or TERN? Tenaya Therapeutics currently has a consensus target price of $6.25, suggesting a potential upside of 940.28%. Terns Pharmaceuticals has a consensus target price of $15.63, suggesting a potential upside of 297.58%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Tenaya Therapeutics is more favorable than Terns Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenaya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Terns Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has more volatility and risk, TNYA or TERN? Tenaya Therapeutics has a beta of 2.91, indicating that its share price is 191% more volatile than the S&P 500. Comparatively, Terns Pharmaceuticals has a beta of -0.18, indicating that its share price is 118% less volatile than the S&P 500. Does the media prefer TNYA or TERN? In the previous week, Tenaya Therapeutics and Tenaya Therapeutics both had 3 articles in the media. Terns Pharmaceuticals' average media sentiment score of 1.52 beat Tenaya Therapeutics' score of 0.97 indicating that Terns Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Terns Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Does the MarketBeat Community believe in TNYA or TERN? Tenaya Therapeutics and Terns Pharmaceuticals both received 44 outperform votes by MarketBeat users. However, 84.62% of users gave Tenaya Therapeutics an outperform vote while only 60.27% of users gave Terns Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTenaya TherapeuticsOutperform Votes4484.62% Underperform Votes815.38%Terns PharmaceuticalsOutperform Votes4460.27% Underperform Votes2939.73% Do institutionals and insiders hold more shares of TNYA or TERN? 90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 98.3% of Terns Pharmaceuticals shares are held by institutional investors. 48.7% of Tenaya Therapeutics shares are held by insiders. Comparatively, 1.5% of Terns Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has preferable valuation and earnings, TNYA or TERN? Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenaya TherapeuticsN/AN/A-$124.08M-$1.16-0.52Terns PharmaceuticalsN/AN/A-$90.21M-$1.09-3.61 SummaryTenaya Therapeutics beats Terns Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNYA vs. The Competition Export to ExcelMetricTenaya TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$97.73M$3.12B$5.61B$8.62BDividend YieldN/A1.56%5.28%4.17%P/E Ratio-0.4232.9027.2119.96Price / SalesN/A466.20408.49157.63Price / CashN/A168.6838.2534.64Price / Book0.293.427.074.69Net Income-$124.08M-$72.35M$3.23B$248.14M7 Day Performance-5.21%2.59%0.68%0.91%1 Month Performance52.33%20.47%9.59%5.71%1 Year Performance-83.94%-17.11%32.02%14.71% Tenaya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNYATenaya Therapeutics3.8397 of 5 stars$0.60-4.9%$6.25+940.3%-84.2%$97.73MN/A-0.42110News CoverageTERNTerns Pharmaceuticals4.1719 of 5 stars$3.28+5.4%$15.63+376.5%-46.8%$285.16MN/A-2.7740Positive NewsTNGXTango Therapeutics2.1763 of 5 stars$2.60+17.1%$12.20+369.2%-33.6%$283.56M$40.99M-2.2290Trending NewsAnalyst RevisionGap DownHigh Trading VolumeAQSTAquestive Therapeutics1.7562 of 5 stars$2.85+5.0%$10.14+256.5%+17.8%$282.59M$54.23M-6.32160Positive NewsAnalyst RevisionGLUEMonte Rosa Therapeutics2.4015 of 5 stars$4.56+9.1%$15.50+239.9%+18.3%$281.35M$159.49M-2.5090ALLOAllogene Therapeutics3.9881 of 5 stars$1.29+9.8%$8.44+557.2%-45.5%$281.07M$22K-0.82310Positive NewsTVRDCara TherapeuticsN/A$29.98+5.8%$65.00+116.8%N/A$280.64MN/A0.0080News CoverageAnalyst ForecastHigh Trading VolumePVLAPalvella Therapeutics4.0235 of 5 stars$25.38+5.2%$46.29+82.4%N/A$280.60M$42.81M-2.10N/APositive NewsAnalyst RevisionCADLCandel Therapeutics3.1303 of 5 stars$5.57+2.1%$21.00+277.4%-29.3%$280.33M$120K-3.2360Positive NewsTNXPTonix Pharmaceuticals3.3868 of 5 stars$37.75-5.1%$585.00+1,449.6%-68.9%$277.80M$10.04M-0.0150News CoverageGap DownCYRXCryoport3.484 of 5 stars$5.45-9.3%$11.00+101.8%-34.8%$276.00M$232.13M-1.631,020News CoverageInsider Trade Related Companies and Tools Related Companies Terns Pharmaceuticals Competitors Tango Therapeutics Competitors Aquestive Therapeutics Competitors Monte Rosa Therapeutics Competitors Allogene Therapeutics Competitors Cara Therapeutics Competitors Palvella Therapeutics Competitors Candel Therapeutics Competitors Tonix Pharmaceuticals Competitors Cryoport Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNYA) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
